JPMorgan Chase & Co. set a CHF 84 target price on Novartis (VTX:NOVN) in a research report released on Wednesday morning. The brokerage currently has a neutral rating on the stock.

Several other research firms have also issued reports on NOVN. UBS Group set a CHF 78 target price on Novartis and gave the stock a neutral rating in a report on Monday, October 23rd. Morgan Stanley set a CHF 88 target price on Novartis and gave the stock a buy rating in a report on Friday, October 20th. Deutsche Bank set a CHF 83.50 target price on Novartis and gave the stock a neutral rating in a report on Wednesday, October 4th. S&P Global set a CHF 87 target price on Novartis and gave the stock a neutral rating in a report on Tuesday, October 24th. Finally, set a CHF 90 target price on Novartis and gave the stock a buy rating in a report on Monday, October 30th. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and seven have issued a buy rating to the stock. Novartis currently has an average rating of Hold and a consensus target price of CHF 86.97.

Shares of Novartis (VTX:NOVN) opened at CHF 83.88 on Wednesday. The stock has a market capitalization of $218,960.00 and a price-to-earnings ratio of 30.61. Novartis has a 1-year low of CHF 69.50 and a 1-year high of CHF 85.40.

ILLEGAL ACTIVITY NOTICE: “Novartis (NOVN) PT Set at CHF 84 by JPMorgan Chase & Co.” was first reported by Watch List News and is owned by of Watch List News. If you are reading this story on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this story can be read at https://www.watchlistnews.com/novartis-novn-pt-set-at-chf-84-by-jpmorgan-chase-co/1805187.html.

Novartis Company Profile

Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.